Arvinas, Inc. (ARVN)
Price:
9.59 USD
( - -0.16 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
United Therapeutics Corporation
VALUE SCORE:
9
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
NEWS
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
globenewswire.com
2025-10-05 14:00:00– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease –
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
globenewswire.com
2025-10-01 07:00:00NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that two presentations, including one e-poster session and one oral platform presentation, featuring clinical data for ARV-102, an investigational oral PROTAC (PROteolysis TArgeting Chimera) degrader of leucine-rich repeat kinase 2 (LRRK2), will be presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders® (MDS 2025) being held October 5–9, 2025, in Honolulu.
Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party
reuters.com
2025-09-17 17:50:16Drug developer Arvinas said on Wednesday it will grant commercialization rights of an experimental breast cancer treatment it was developing with Pfizer to a third party.
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
globenewswire.com
2025-09-17 16:30:00Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board authorizes stock repurchase program of up to $100 million Reaffirms cash runway guidance through the second half of 2028 NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today provided an update on its collaboration with Pfizer Inc. (NYSE: PFE) for the co-development of vepdegestrant, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader, and announced additional corporate actions to support shareholder value creation.
Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
seekingalpha.com
2025-09-09 10:12:22Arvinas, Inc. (NASDAQ:ARVN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants John Houston - Chairperson, CEO & President Noah Berkowitz - Chief Medical Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with the afternoon session.
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
globenewswire.com
2025-08-08 16:05:00– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –
Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-06 13:24:06Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates
zacks.com
2025-08-06 09:15:36Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
2025-08-06 07:00:00– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer –
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
globenewswire.com
2025-07-30 16:05:00NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the second quarter of 2025 and provide a corporate update during a live webcast on Wednesday, August 6, 2025, at 8:00 a.m. ET.
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
globenewswire.com
2025-07-09 07:00:00– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn.
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
zacks.com
2025-06-16 10:56:12The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
globenewswire.com
2025-06-13 07:00:00– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma –
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
prnewswire.com
2025-06-07 10:00:00NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
globenewswire.com
2025-06-06 12:20:00NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
No data to display
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
globenewswire.com
2025-10-05 14:00:00– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease –
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
globenewswire.com
2025-10-01 07:00:00NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that two presentations, including one e-poster session and one oral platform presentation, featuring clinical data for ARV-102, an investigational oral PROTAC (PROteolysis TArgeting Chimera) degrader of leucine-rich repeat kinase 2 (LRRK2), will be presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders® (MDS 2025) being held October 5–9, 2025, in Honolulu.
Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party
reuters.com
2025-09-17 17:50:16Drug developer Arvinas said on Wednesday it will grant commercialization rights of an experimental breast cancer treatment it was developing with Pfizer to a third party.
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
globenewswire.com
2025-09-17 16:30:00Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board authorizes stock repurchase program of up to $100 million Reaffirms cash runway guidance through the second half of 2028 NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today provided an update on its collaboration with Pfizer Inc. (NYSE: PFE) for the co-development of vepdegestrant, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader, and announced additional corporate actions to support shareholder value creation.
Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
seekingalpha.com
2025-09-09 10:12:22Arvinas, Inc. (NASDAQ:ARVN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants John Houston - Chairperson, CEO & President Noah Berkowitz - Chief Medical Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with the afternoon session.
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
globenewswire.com
2025-08-08 16:05:00– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –
Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-06 13:24:06Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates
zacks.com
2025-08-06 09:15:36Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
2025-08-06 07:00:00– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer –
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
globenewswire.com
2025-07-30 16:05:00NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the second quarter of 2025 and provide a corporate update during a live webcast on Wednesday, August 6, 2025, at 8:00 a.m. ET.
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
globenewswire.com
2025-07-09 07:00:00– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn.
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
zacks.com
2025-06-16 10:56:12The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
globenewswire.com
2025-06-13 07:00:00– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma –
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
prnewswire.com
2025-06-07 10:00:00NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
globenewswire.com
2025-06-06 12:20:00NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.